London Technology Fund
6
5M
4
0.38
2
0.33
1
- Stages of investment
- Areas of investment
Summary
In 2005 was created London Technology Fund, which is appeared as VC. The main office of represented VC is situated in the London. The venture was found in Europe in United Kingdom.
Besides, a startup needs to be aged 4-5 years to get the investment from the fund. We can highlight the next thriving fund investment areas, such as Biotechnology, Product Design. Among the most popular portfolio startups of the fund, we may highlight Immune Targeting Systems, deltaDOT. For fund there is a match between the location of its establishment and the land of its numerous investments - United Kingdom.
The usual cause for the fund is to invest in rounds with 2-3 partakers. Despite the London Technology Fund, startups are often financed by Truffle Capital, Novartis Venture Fund, Nikko Principal Investments. The meaningful sponsors for the fund in investment in the same round are Truffle Capital, Novartis Venture Fund, Imperial Innovations. In the next rounds fund is usually obtained by Truffle Capital, Royal Society Enterprise Fund, Novartis Venture Fund.
Opposing the other organizations, this London Technology Fund works on 12 percentage points less the average amount of lead investments. The fund is generally included in less than 2 deals every year. Considering the real fund results, this VC is 13 percentage points more often commits exit comparing to other organizations. The common things for fund are deals in the range of 1 - 5 millions dollars. The top activity for fund was in 2007. The top amount of exits for fund were in 2015.
Investments analytics
Analytics
- Total investments
- 6
- Lead investments
- 2
- Exits
- 1
- Rounds per year
- 0.38
- Follow on index
- 0.33
- Investments by industry
- Biotechnology (3)
- Product Design (2)
- Developer Tools (2)
- Health Care (2)
- Medical (2) Show 5 more
- Investments by region
-
- United Kingdom (6)
- Peak activity year
- 2007
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 18
- Group Appearance index
- 0.83
- Avg. company exit year
- 12
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
Company name | Deal date | Industry | Deal stage | Deal size | Location |
---|---|---|---|---|---|
Immune Targeting Systems | 17 Mar 2010 | Biotechnology, Health Care, Medical | Early Stage Venture | 13M | United Kingdom, London, England |
Similar funds
By same location
By same geo focus
By doing lead investments
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.